CL2014001247A1 - Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion. - Google Patents

Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion.

Info

Publication number
CL2014001247A1
CL2014001247A1 CL2014001247A CL2014001247A CL2014001247A1 CL 2014001247 A1 CL2014001247 A1 CL 2014001247A1 CL 2014001247 A CL2014001247 A CL 2014001247A CL 2014001247 A CL2014001247 A CL 2014001247A CL 2014001247 A1 CL2014001247 A1 CL 2014001247A1
Authority
CL
Chile
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
trifluoro
Prior art date
Application number
CL2014001247A
Other languages
English (en)
Spanish (es)
Inventor
Upkar Bhardwaj
Mangesh Sadashlv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2014001247A1 publication Critical patent/CL2014001247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2014001247A 2011-11-14 2014-05-13 Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion. CL2014001247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14

Publications (1)

Publication Number Publication Date
CL2014001247A1 true CL2014001247A1 (es) 2014-10-17

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001247A CL2014001247A1 (es) 2011-11-14 2014-05-13 Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion.

Country Status (23)

Country Link
EP (1) EP2779995A1 (enExample)
JP (1) JP6275645B2 (enExample)
KR (1) KR20140093230A (enExample)
CN (1) CN103930094A (enExample)
AR (1) AR088844A1 (enExample)
BR (1) BR112014011518A2 (enExample)
CA (1) CA2855503A1 (enExample)
CL (1) CL2014001247A1 (enExample)
CO (1) CO6960546A2 (enExample)
EA (1) EA201490960A1 (enExample)
GT (1) GT201400094A (enExample)
HK (1) HK1197025A1 (enExample)
IL (1) IL232480A0 (enExample)
IN (1) IN2014DN03416A (enExample)
MA (1) MA35636B1 (enExample)
MX (1) MX2014005874A (enExample)
PE (1) PE20141337A1 (enExample)
PH (1) PH12014501062B1 (enExample)
SG (2) SG11201401476TA (enExample)
TN (1) TN2014000177A1 (enExample)
TW (1) TWI574690B (enExample)
WO (1) WO2013074432A1 (enExample)
ZA (1) ZA201402756B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) * 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤
JP7776274B2 (ja) * 2021-07-19 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法
JP7776275B2 (ja) * 2021-07-26 2025-11-26 日本化薬株式会社 ニロチニブ錠剤およびその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (enExample) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
HK1197025A1 (en) 2015-01-02
MA35636B1 (fr) 2014-11-01
EP2779995A1 (en) 2014-09-24
KR20140093230A (ko) 2014-07-25
BR112014011518A2 (pt) 2017-05-16
NZ623844A (en) 2016-09-30
TWI574690B (zh) 2017-03-21
WO2013074432A1 (en) 2013-05-23
JP2014533283A (ja) 2014-12-11
CN103930094A (zh) 2014-07-16
GT201400094A (es) 2017-09-28
AU2012339829A1 (en) 2014-05-29
EA201490960A1 (ru) 2014-08-29
AR088844A1 (es) 2014-07-10
IL232480A0 (en) 2014-06-30
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30
CO6960546A2 (es) 2014-05-30
PE20141337A1 (es) 2014-10-16
ZA201402756B (en) 2015-04-29
JP6275645B2 (ja) 2018-02-07
PH12014501062A1 (en) 2014-06-23
TW201325594A (zh) 2013-07-01
SG10201707768RA (en) 2017-10-30
CA2855503A1 (en) 2013-05-23
SG11201401476TA (en) 2014-10-30
PH12014501062B1 (en) 2018-04-20
AU2012339829B2 (en) 2016-05-12
IN2014DN03416A (enExample) 2015-06-26

Similar Documents

Publication Publication Date Title
CO6801777A2 (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
IL288009A (en) Use of proton tyrosine kinase inhibitors
CL2014001247A1 (es) Forma de dosificacion solida de liberacion inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida; metodo de preparacion.
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
DK2878598T3 (da) Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
IL236495A0 (en) Heteroaromatic compounds as proton tyrosine kinase inhibitors
CO6811863A2 (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
HUE037154T2 (hu) Szubsztituált benzilindazol-származékok mint Bub1 kinázgátlók hiperproliferatív megbetegedések kezelésére
PE20121476A1 (es) Composicion para el tratamiento de trastornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r
SI2632921T1 (sl) Polimorfi in soli 6-(1H- indol-4-il)-4-(5-((4-(1-metiletil)-1-piperazinil)metil)-1,3-oksazol-2- il)-1H-indazola kot inhibitorji PI3K za uporabo pri zdravljenju npr. respiratornih motenj
WO2013150545A8 (en) Process for preparation of benzimidazole derivatives and salts thereof
SI3077390T1 (sl) Kristalinična oblika soli (s)-(2-(6-kloro-7-metil-1h-benzo(d)imidazol-2-il)-2-metilpirolidin-1-il) (5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanona kot antagonista oreksinskih receptorjev
IL231958A0 (en) Solid dosage forms of (s)-ethyl-2-amino-3-(4-(2-amino-6(r)-1-(4-chloro-2-(3-methyl-h1-pyrazol-1-yl )-2,2,2-trifluoroethoxy)pyrimidine-4-yl(phenyl)propanoate
PT2943488T (pt) Formas de sal de meglumina do ácido 2-((1r,4r)-4-(4-(5- (benzoxazol-2-ilamina)piridin-2-il)fenil)ciclohexil) acético e sua utilização como inibidores de dgat1
HK1193102A (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
BR112013025679A2 (pt) inibidores de proteína quinase de novos compostos de indolinona
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก